Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its ...

GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell ...

The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

The preventive duration requires individualised adjustment by clinicians based on the patient’s condition, undeniably complicating clinical management. Based on current guidelines and expert consensus ...

Su Jin Yim and colleagues argue that with the proposed definition of Alzheimer’s disease (AD) expanding in the most recent ...

As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...